Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Psoriasis patients weigh in: is wynzora cream the new favorite?

NCT ID NCT06180473

Symptom relief Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This study looked at whether people with mild-to-moderate psoriasis prefer using Wynzora cream over Enstilar foam. Thirty adults who had previously used Enstilar foam tried Wynzora cream for four weeks. Researchers used questionnaires to measure preference, treatment satisfaction, and how well patients followed their treatment plan.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Wynzora cream (calcipotriene and betamethasone dipropionate)
What this could lead to
If successful, this could show that Wynzora cream is a more preferred or easier-to-use option for managing mild-to-moderate psoriasis compared to Enstilar foam.
What could go wrong
This is a small, completed study with only 30 participants, so results may not apply to everyone. It measures preference and adherence, not long-term disease control or cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

30 people

The number who actually took part.

Started

Jan 2024

Finished

Jun 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients diagnosed with psoriasis will be enrolled, who will be according to clinical practice will be prescribed treatment with Wynzora cream for 30 consecutive days, referring to the Dermatology and Venereology outpatient clinics of the Fondazione Policlinico Universitario A. Gemelli, IRCCS Rome

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients older than 18 years of age, of either sex; * Patients diagnosed with mild-to-moderate psoriasis (PASI and BSA \<10) requiring monotherapy topical with Wynzora; * Patients who have stopped treatment with Enstilar foam for any reason for at least 30 days; and * Patients whose medical records are accessible and record all demographic parameters, anthropometric and clinical parameters during the treatment period * Signature of written informed consent; Exclusion Criteria: * Patients with palmoplantar, inverse, erythrodermic, guttate, and scalp psoriasis. * Patients who are taking concomitant systemic therapies for psoriasis, such as. cyclosporine, methotrexate, acitretin, phototherapy or biologic therapies. * Women who are pregnant or planning to become pregnant. * Patients with disabilities or other motor problems that could complicate self-medication.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psoriasis

Contacts and locations

Locations

  • Policlinico Agostino Gemelli

    Rome, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.